A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 10, Pages 2145-2154
Publisher
Springer Science and Business Media LLC
Online
2022-09-23
DOI
10.1038/s41591-022-01969-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
- (2022) Jordan Gauthier et al. BLOOD
- GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
- (2022) Wolfgang Andreas Bethge et al. BLOOD
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Olalekan O. Oluwole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
- (2021) David G. Maloney et al. Journal of Hematology & Oncology
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
- (2021) Stephen J Schuster et al. LANCET ONCOLOGY
- A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
- (2021) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
- (2021) Caron Jacobson et al. BLOOD
- Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Max S. Topp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
- (2021) Nathan Hale Fowler et al. NATURE MEDICINE
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- (2021) Michael R. Bishop et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
- (2020) Victoria Allan et al. Journal of Comparative Effectiveness Research
- A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
- (2020) Jie Zhang et al. ADVANCES IN THERAPY
- Use of Commercial anti‐CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center
- (2020) Pierre Sesques et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma
- (2020) Olalekan O. Oluwole et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- Letter to the Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”
- (2020) Jie Zhang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Frederick L. Locke et al. Blood Advances
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments
- (2013) Peter C. Austin STATISTICS IN MEDICINE
- Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
- (2012) James E. Signorovitch et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started